ResearcherUniversity of North Carolina at CharlotteActive in the last 2 years

Cassandra Catacalos-Goad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-0869-1722; OpenAlex author ID A5115813246. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2025: 2 papers

Papers 2

Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus. Co-author DOI 10.1016/j.omton.2025.201089 ↗
METTL3 depletion blocks vesicular stomatitis virus replication in pancreatic cancer cells through the establishment of an intrinsic antiviral state. Co-author DOI 10.1128/jvi.02284-24 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Valery Z. Grdzelishvili · 2 shared papers, 2025 · strength 0.61
- Paper METTL3 depletion blocks vesicular stomatitis virus replication in pancreatic cancer cells through the establishment of … DOI 10.1128/jvi.02284-24 ↗
- Paper Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stom… DOI 10.1016/j.omton.2025.201089 ↗
Dakota W. Goad · 1 shared paper, 2025 · strength 0.28
- Paper Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stom… DOI 10.1016/j.omton.2025.201089 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.